Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole in Schizophrenia and Schizoaffective Disorder
NCT00292409Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2005
- Primary completion
- Nov 2007
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of aripiprazole in schizophrenia, schizoaffective disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Mar 2005; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00292409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292409.